Biotech Values

[genisi]

apparently we now learned that many nulls are in fact resistant to ribavirin - or else how do you explain the difference (even in these small numbers) between the treatment naive and null populations in the 7977 study

There are several variables we should consider when looking at 7997 data: GT1 vs GT2/3 and null vs naïve.
Riba could be too weak in GT1 and potent enough in GT2/3 or perhaps nulls are resistant to Riba as you suggested. Either way, replacing Riba with a more potent DAA should help. The other possibility is that an agent with different MoA (not a DAA but like IFN) is needed for viral clearance and cure. I'm leaning toward the first.